Selective Janus kinase inhibitors come of age

Affiliations

¹ Molecular Immunology and Inflammation Branch, National Institutes of Arthritis and Musculoskeletal and Skin diseases, Bethesda, MD, USA. john.oshea@nih.gov.
² Translational Immunology Section, National Institutes of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, USA.

John J O'Shea et al. Nat Rev Rheumatol. 2019 Feb.

. 2019 Feb;15(2):74-75.

doi: 10.1038/s41584-018-0155-9.

¹ Molecular Immunology and Inflammation Branch, National Institutes of Arthritis and Musculoskeletal and Skin diseases, Bethesda, MD, USA. john.oshea@nih.gov.
² Translational Immunology Section, National Institutes of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, USA.

No abstract available

References

1. Mease, P. et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial. Lancet 392, 2367–2377 (2018). - DOI
1. van der Heijde, D. et al. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial. Lancet 392, 2378–2387 (2018). - DOI
1. Burmester, G. R. et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 391, 2503–2512 (2018). - DOI
1. Genovese, M. C. et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet 391, 2513–2524 (2018). - DOI
1. Gadina, M. et al. Translational and clinical advances in JAK-STAT biology: the present and future of jakinibs. J. Leukoc. Biol. 104, 499–514 (2018). - DOI